Lapse

Lapse ranks brand-name drugs by how good a generic or biosimilar target they'd be. The patent cliff behind it is huge: $200B+ in drug sales lose protection between 2025 and 2030, and working out which ones are worth chasing is normally a manual slog across a bunch of FDA and CMS databases. Lapse does that ranking automatically. All Bruin under the hood: ingestion assets pull the Orange Book, Purple Book, and CMS Part B/D spending; SQL assets join and score it in DuckDB; and the MCP analyst answers things like "which drugs lose protection in the next 18 months with a big market and few generic filers." Live: <https://lapse.health>